Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Baricitinib

FDA-approved product (tablet, oral), marketed as Baricitinib, Olumiant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Baricitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Baricitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Baricitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial

    NCT04399798 · start 2020-05-15

    Registered record
    Registry ID
    NCT04399798
    Conditions
    Corona Virus Infection
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-05-15
    Completion
    2020-11-15
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorona Virus Infection
    InterventionBaricitinib
    PhasePhase 2
    Registry statusUnknown

  • Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

    NCT04373044 · start 2020-05-01

    Registered record
    Registry ID
    NCT04373044
    Conditions
    Symptomatic COVID-19 Infection Laboratory-Confirmed
    Interventions
    Baricitinib; Hydroxychloroquine; Placebo Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-05-01
    Completion
    2021-05-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSymptomatic COVID-19 Infection Laboratory-Confirmed
    InterventionBaricitinib; Hydroxychloroquine; Placebo Administration
    PhasePhase 2
    Registry statusTerminated

  • Randomised Evaluation of COVID-19 Therapy

    NCT04381936 · start 2020-03-19

    Registered record
    Registry ID
    NCT04381936
    Conditions
    Pneumonia
    Interventions
    Lopinavir-Ritonavir; Corticosteroid; Hydroxychloroquine; Azithromycin; Convalescent plasma; Tocilizumab; Immunoglobulin; Synthetic neutralising antibodies; Aspirin; Colchicine; Baricitinib; Anakinra; Dimethyl fumarate; High Dose Corticosteroid; Empagliflozin; Sotrovimab; Molnupiravir; Paxlovid; Baloxavir Marboxil; Oseltamivir; Corticosteroids (dexamethasone); Corticosteroids (dexamethasone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-03-19
    Completion
    2038-09-30
    Enrolment
    70,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionLopinavir-Ritonavir; Corticosteroid; Hydroxychloroquine; Azithromycin +18 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Baricitinib in Participants With Rheumatoid Arthritis

    NCT04086745 · start 2020-02-14

    Registered record
    Registry ID
    NCT04086745
    Conditions
    Rheumatoid Arthritis
    Interventions
    Baricitinib; TNF Inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-14
    Completion
    2025-05-19
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionBaricitinib; TNF Inhibitor
    PhasePhase 4
    Registry statusCompleted

  • A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

    NCT03843125 · start 2019-09-09

    Registered record
    Registry ID
    NCT03843125
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    Baricitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-09-09
    Completion
    2022-04-01
    Enrolment
    1,147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionBaricitinib; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

    NCT03899259 · start 2019-07-08

    Registered record
    Registry ID
    NCT03899259
    Conditions
    Alopecia Areata
    Interventions
    Baricitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-08
    Completion
    2024-11-19
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionBaricitinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

    NCT03773965 · start 2019-04-05

    Registered record
    Registry ID
    NCT03773965
    Conditions
    Juvenile Idiopathic Arthritis
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2019-04-05
    Completion
    2031-07
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis
    InterventionBaricitinib
    PhasePhase 3
    Registry statusRecruiting

  • Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

    NCT05674695 · start 2019-01-01

    Registered record
    Registry ID
    NCT05674695
    Conditions
    Dermatitis, Atopic
    Interventions
    Ciclosporin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-01
    Completion
    2029-01-01
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionCiclosporin
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

    NCT03334422 · start 2017-11-27

    Registered record
    Registry ID
    NCT03334422
    Conditions
    Atopic Dermatitis
    Interventions
    Baricitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-27
    Completion
    2018-12-12
    Enrolment
    615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionBaricitinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

    NCT02576938 · start 2016-02

    Registered record
    Registry ID
    NCT02576938
    Conditions
    Atopic Dermatitis
    Interventions
    Baricitinib; Placebo; Triamcinolone (Optional)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-02
    Completion
    2017-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionBaricitinib; Placebo; Triamcinolone (Optional)
    PhasePhase 2
    Registry statusCompleted

  • A Study of Baricitinib in Healthy Japanese Participants

    NCT02263911 · start 2014-11

    Registered record
    Registry ID
    NCT02263911
    Conditions
    Healthy Participants
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    2014-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBaricitinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)

    NCT02265705 · start 2014-10

    Registered record
    Registry ID
    NCT02265705
    Conditions
    Rheumatoid Arthritis
    Interventions
    Baricitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2017-05
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionBaricitinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Baricitinib and Omeprazole in Healthy Participants

    NCT01925144 · start 2013-10

    Registered record
    Registry ID
    NCT01925144
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of Baricitinib and Simvastatin in Healthy Participants

    NCT01960140 · start 2013-10

    Registered record
    Registry ID
    NCT01960140
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Simvastatin
    PhasePhase 1
    Registry statusCompleted

  • A Study of Baricitinib and Ciclosporin in Healthy Participants

    NCT01968057 · start 2013-10

    Registered record
    Registry ID
    NCT01968057
    Conditions
    Healthy Volunteers
    Interventions
    Baricitinib; Ciclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBaricitinib; Ciclosporin
    PhasePhase 1
    Registry statusCompleted